Navigation Links
Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
Date:8/22/2007

MENLO PARK, Calif. and HUNTSVILLE, Ala., Aug. 22 /PRNewswire/ -- DNA2.0 Inc. (http://www.DNA20.com), the largest US provider of synthetic genes, and Operon Biotechnologies (http://www.operon.com), a leader in DNA oligonucleotide synthesis, announce the formation of a partnership to utilize their synergistic technologies and product lines.

By combining Operon's oligonucleotide production platform with DNA2.0's gene synthesis process, the companies expect to further increase DNA2.0's market leading speed of synthesis, while providing Operon access to the fastest growing application area for oligonucleotides today. The partnership will allow each company to remain focused on their respective core businesses, while the customer benefits from the expertise of both partners.

Under the partnership, Operon will co-market DNA2.0's gene synthesis services. 'DNA2.0 provides products and a level of customer service that is unparalleled in the gene synthesis industry, we wholeheartedly recommend them to our customers for their synthetic genes.' said Patrick A. Weiss, CEO of Operon. 'We at Operon are proud to be the primary source of the oligos that go into DNA2.0 synthetic genes.'

'Construction of synthetic genes requires oligos of only the highest quality' said Jeremy Minshull, President of DNA2.0. 'Operon's fully automated oligo synthesis process meets our exacting quality requirements, and their speed and responsiveness makes Operon an outstanding partner for DNA2.0 in the gene synthesis marketplace.'

About DNA2.0 Inc.

DNA2.0 is the largest US provider of synthetic genes, serving customers globally in the pharmaceutical and biotechnology industries as well as in academia. The company is also pioneering the application of machine learning to commercial protein engineering through their ProteinGPS(TM) platform. For more information please visit http://www.DNA20.com.

About Operon Biotechnologies

Operon Biotechnologies is a global market leader in high-throughput synthesis, serving scientists in academic research, biotechnology, and pharmaceutical development. Through our production facilities in the US, Germany, and Japan, as well as distributors worldwide, Operon provides a wide range of quality DNA oligonucleotides, Array Ready Oligo Sets (AROS(TM)) and pre-printed microarrays (OpArray(TM)). Since its inception in 1986, Operon has been driven by incomparable customer service and reliable delivery of quality products. Operon employs advanced synthesis technologies and consistently pursues unique innovations to maintain the highest level of excellence in both products and support. For more information please visit http://www.operon.com.


'/>"/>
SOURCE Operon Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):